Search clinical trials for: Placebo, MK-0431/ONO-5435

Total 1286 results

Merck Sharp & Dohme LLC

Terminated

A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC
Duke Clinical Research Institute, Oxford Diabetes Trials Unit

Completed

Sitagliptin Cardiovascular Outcomes Study (MK-0431-082) (TECOS)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Cerenis Therapeutics, SA

Terminated

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (TANGO)

Familial Hypoalphalipoproteinemia

France, United States, Belgium, Canada, Israel, Italy, Netherlands
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Novo Nordisk A/S

Completed

A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease

Atherosclerotic Cardiovascular Disease

Germany, Poland, United States, Netherlands, Japan, Greece, Belgium
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom, South Africa
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)

Type 2 Diabetes
Royal Adelaide Hospital
Merck Sharp & Dohme LLC

Completed

Effects of Sitagliptin on Gastric Emptying in Healthy Subjects

Diabetes Mellitus | Gastroparesis

Australia
Merck Sharp & Dohme LLC

Completed

Pharmacokinetics of Peginterferon Alfa-2b in Participants With Moderate and Severe Renal Impairment (P05655)

Renal Insufficiency
Fujian Shengdi Pharmaceutical Co., Ltd.

Recruiting

Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration of HRS-5635 Injection in Chinese Healthy Subjects and the Safety, Tolerance, Pharmacokinetics and Antiviral Effect of Multiple Administration in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Bipolar I Disorder

United States
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Non-segmental Vitiligo

United States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium, Argentina
Merck Sharp & Dohme LLC

Completed

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Cancer | Pharmacokinetics

Belgium
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Migraine | Headache
Merck Sharp & Dohme LLC

Completed

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

Depression
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)

Hepatitis C
Merck Sharp & Dohme LLC

Recruiting

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Narcolepsy

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Systemic Lupus Erythematosus

United States, Canada, Japan, Chile, France, Poland, Spain, Guatemala, Italy
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Completed

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Postherpetic Neuralgia
Merck Sharp & Dohme LLC

Completed

Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)

Diabetic Neuropathy, Painful
Merck Sharp & Dohme LLC

Completed

Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

Attention Deficit Hyperactivity Disorder
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Efficacy of MK0773 in Healthy Postmenopausal Women (0773-003)

Osteoporosis
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8266 in Hypertensive Men (MK-8266-002)

Hypertension
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Kidney Failure, Chronic | End-Stage Renal Disease | End-Stage Kidney Disease

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)

Dermatitis, Atopic

United States, Belgium, Bulgaria, Canada, Romania, Spain
Merck Sharp & Dohme LLC

Completed

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Kidney Failure, Chronic | Renal Dialysis

United States
Merck Sharp & Dohme LLC

Terminated

A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)

Atopic Dermatitis
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of MK-8266 in Elderly Participants With High Blood Pressure (MK-8266-003)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)

Pharmacokinetics
Merck Sharp & Dohme LLC

Completed

MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005)

Diabetes Mellitus, Non-Insulin-Dependent
University of California, Los Angeles
Massachusetts General Hospital; Washington University School of Medicine; University... and other collaborators

Completed

Treatment Study for Cognitive Deficits in Schizophrenia (TURNS)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin Versus Glipizide in Participants With Type 2 Diabetes Mellitus and Chronic Renal Insufficiency (MK-0431-063 AM1)

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

HIV Infections

United States
Merck Sharp & Dohme LLC

Completed

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

Urinary Incontinence
Merck Sharp & Dohme LLC

Completed

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)

Type 2 Diabetes Mellitus
Royal Adelaide Hospital

Completed

Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes

Diabetes Mellitus | Gastroparesis

Australia
Pardes Biosciences, Inc.

Active, not recruiting

PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19

COVID-19

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

Respiratory Syncytial Virus | Respiratory Tract Infection

United States, Chile, Colombia, Korea, Republic of, South Africa, Spain

3

Subscribe